ZA200203394B - Pharmaceutical compositions. - Google Patents

Pharmaceutical compositions. Download PDF

Info

Publication number
ZA200203394B
ZA200203394B ZA200203394A ZA200203394A ZA200203394B ZA 200203394 B ZA200203394 B ZA 200203394B ZA 200203394 A ZA200203394 A ZA 200203394A ZA 200203394 A ZA200203394 A ZA 200203394A ZA 200203394 B ZA200203394 B ZA 200203394B
Authority
ZA
South Africa
Prior art keywords
oxcarbazepine
dosage form
oral dosage
patient
food
Prior art date
Application number
ZA200203394A
Other languages
English (en)
Inventor
Steffen Lang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200203394B publication Critical patent/ZA200203394B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200203394A 1999-11-02 2002-04-29 Pharmaceutical compositions. ZA200203394B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925962.4A GB9925962D0 (en) 1999-11-02 1999-11-02 Organic compounds

Publications (1)

Publication Number Publication Date
ZA200203394B true ZA200203394B (en) 2003-07-29

Family

ID=10863836

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203394A ZA200203394B (en) 1999-11-02 2002-04-29 Pharmaceutical compositions.

Country Status (25)

Country Link
US (3) US20060079502A1 (cs)
EP (1) EP1242091B1 (cs)
JP (3) JP2003514780A (cs)
KR (1) KR100493836B1 (cs)
CN (1) CN1407894A (cs)
AT (1) ATE401892T1 (cs)
AU (1) AU777705B2 (cs)
BR (1) BR0015188A (cs)
CA (1) CA2388609C (cs)
CZ (1) CZ302847B6 (cs)
DE (1) DE60039629D1 (cs)
ES (1) ES2311001T3 (cs)
GB (1) GB9925962D0 (cs)
HK (1) HK1050839B (cs)
HU (1) HU227685B1 (cs)
IL (3) IL149147A0 (cs)
MX (1) MXPA02004389A (cs)
NO (1) NO330947B1 (cs)
NZ (1) NZ518378A (cs)
PL (1) PL200273B1 (cs)
RU (1) RU2330666C2 (cs)
SK (1) SK287479B6 (cs)
TR (1) TR200200951T2 (cs)
WO (1) WO2001032183A2 (cs)
ZA (1) ZA200203394B (cs)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
MXPA04011801A (es) * 2002-05-31 2005-09-12 Desitin Arzneimittel Gmbh Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa.
CA2494660A1 (en) * 2002-08-06 2004-02-19 Novartis Ag Use of carboxamides for the treatment of tinnitus
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
BRPI0414112A (pt) * 2003-09-03 2006-10-31 Novartis Ag uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
RU2384339C2 (ru) * 2004-04-13 2010-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Применение симетикона для предрасположенных к запорам пациентов
WO2006046105A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Oxcarbazepine dosage forms
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007008576A2 (en) * 2005-07-08 2007-01-18 Taro Pharmaceuticals U.S.A., Inc. Oxcarbazepine formulation
WO2007029093A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of oxcarbazepine
CA2634879A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of oxcarbazepine and methods for its preparation
JP2008538783A (ja) * 2006-01-31 2008-11-06 テバ ファーマシューティカル インダストリーズ リミティド ブロード且つ多峰性の粒度分布を有するオキシカルバゼピンを含む医薬製剤及びその調製方法
WO2007127630A1 (en) * 2006-04-26 2007-11-08 Supernus Pharmaceuticals, Inc Controlled released preparations of oxcarbazepine having sigmoidal release profile
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
ES2559838T3 (es) 2007-03-16 2016-02-16 Concert Pharmaceuticals, Inc. Inhibidores de proteína de transferencia de ésteres de colesterol
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
BRPI0810362A2 (pt) * 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
EP2527336A1 (en) 2007-04-25 2012-11-28 Concert Pharmaceuticals Inc. Deuterated analogues of cilostazol
EP3632916B1 (en) 2007-05-01 2022-06-08 Concert Pharmaceuticals Inc. Morphinan compounds
CA2685924A1 (en) 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
PL2792662T3 (pl) 2007-05-01 2016-10-31 Związki morfinanu
US7973049B2 (en) 2007-05-01 2011-07-05 Concert Pharmaceuticals Inc. Morphinan compounds
WO2008156632A1 (en) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
EP2265334A2 (en) 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
KR101761427B1 (ko) 2008-09-19 2017-07-25 콘서트 파마슈티컬즈, 인크. 모르피난 화합물
US20120053169A1 (en) 2008-10-30 2012-03-01 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
SI2397158T1 (sl) 2008-10-30 2016-07-29 Concert Pharmaceuticals Inc. Kombinacija spojin morfinana in antidepresivov za zdravljenje psevdobulbarnih vplivov
AU2009311645C1 (en) 2008-11-04 2014-10-02 Acer Therapeutics Inc. CXCR4 receptor compounds
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
EP2454259A1 (en) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
EP2566494B1 (en) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4 receptor compounds
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2012037060A1 (en) 2010-09-13 2012-03-22 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
JP2014506603A (ja) 2011-02-25 2014-03-17 コンサート ファーマシューティカルズ インコーポレイテッド ２−アミノ−ナフチリジン誘導体
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
CA2834574C (en) 2011-05-18 2019-09-17 Concert Pharmaceuticals Inc. Deuterated derivatives of ivacaftor
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2802596A1 (en) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
AU2013245662A1 (en) 2012-04-13 2014-10-30 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
MX360495B (es) 2012-06-15 2018-11-06 Concert Pharmaceuticals Inc Derivados deuterados de ruxolitinib.
US10017445B2 (en) 2012-07-12 2018-07-10 Concert Pharmaceuticals, Inc. Deuterated idebenone
EP3492472A1 (en) 2012-08-17 2019-06-05 Concert Pharmaceuticals Inc. Deuterated baricitinib with improved metabolic stability as jak1 and jak2 kinase inhibitor for treating e.g. rheumatoid arthritis
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
AU2013361320A1 (en) 2012-12-20 2015-07-02 Concert Pharmaceuticals, Inc. Deuterated ALK inhibitors
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
AU2014237569B2 (en) 2013-03-15 2019-03-14 Concert Pharmaceuticals Inc. Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
WO2014150925A2 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Deuterated palbociclib
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
EP3021861A1 (en) 2013-07-18 2016-05-25 Anchor Therapeutics, Inc. Apj receptor compounds
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
WO2015063670A1 (en) * 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
US9694017B2 (en) 2014-02-10 2017-07-04 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
WO2015160913A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
KR102509043B1 (ko) 2014-06-06 2023-03-09 리써치 트라이앵글 인스티튜트 아펠린 수용체(apj) 효능제 및 이의 용도
EP4180041A1 (en) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
US20180243289A1 (en) 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
KR102828163B1 (ko) 2015-09-21 2025-07-02 버텍스 파마슈티칼스 (유럽) 리미티드 중수소화된 cftr 강화제의 투여
EP3377179B1 (en) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Deuterated epi-743
KR20180090852A (ko) 2015-12-09 2018-08-13 리써치 트라이앵글 인스티튜트 개선된 아펠린 수용체(apj) 효능제 및 이의 용도
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
MX388054B (es) 2016-05-04 2025-03-19 Sun Pharmaceutical Ind Inc Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
KR20240013845A (ko) 2016-07-04 2024-01-30 아바니르 파마슈티컬스, 인코포레이티드 중수소화 덱스트로메토르판의 합성 방법
US11596605B2 (en) 2016-08-01 2023-03-07 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
EP3589659B1 (en) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinations for use in the treatment of cancer
WO2018213609A1 (en) 2017-05-17 2018-11-22 Ausubel Frederick M Antibiotic compounds
US11274099B2 (en) 2017-05-19 2022-03-15 Superb Wisdom Limited Derivatives of Resiquimod
US20200368193A1 (en) 2017-11-22 2020-11-26 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
US20220211702A1 (en) 2019-04-10 2022-07-07 Mayo Foundation For Medical Education And Research Methods and materials for gender-dependent treatment of cardiovascular dysfunction
AU2020378438A1 (en) * 2019-11-08 2022-06-02 Lyndra Therapeutics, Inc. Gastric residence systems for administration of active agents
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US20230183203A1 (en) 2020-05-27 2023-06-15 The Penn State Research Foundation Antibacterial compounds
AU2021372512A1 (en) 2020-10-28 2023-06-22 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
EP4384175A1 (en) 2021-08-11 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
JP2025515051A (ja) 2022-05-04 2025-05-13 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 重水素化ｊａｋ阻害剤による治療のための投与レジメン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20020022056A1 (en) * 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets

Also Published As

Publication number Publication date
CZ302847B6 (cs) 2011-12-14
JP2007224041A (ja) 2007-09-06
WO2001032183A3 (en) 2002-07-04
WO2001032183A2 (en) 2001-05-10
US20070037792A1 (en) 2007-02-15
RU2002113752A (ru) 2004-01-10
JP2012211202A (ja) 2012-11-01
PL366314A1 (en) 2005-01-24
GB9925962D0 (en) 1999-12-29
IL149147A0 (en) 2003-01-12
NO330947B1 (no) 2011-08-22
CN1407894A (zh) 2003-04-02
HUP0203556A3 (en) 2004-03-01
TR200200951T2 (tr) 2003-01-21
IL205504A0 (en) 2011-07-31
EP1242091A2 (en) 2002-09-25
NO20022058D0 (no) 2002-04-30
EP1242091B1 (en) 2008-07-23
RU2330666C2 (ru) 2008-08-10
IL149147A (en) 2010-11-30
CA2388609C (en) 2011-01-04
SK5842002A3 (en) 2002-08-06
HK1050839B (en) 2009-01-30
SK287479B6 (sk) 2010-11-08
ES2311001T3 (es) 2009-02-01
NZ518378A (en) 2004-10-29
HUP0203556A2 (hu) 2003-02-28
AU777705B2 (en) 2004-10-28
DE60039629D1 (de) 2008-09-04
JP2003514780A (ja) 2003-04-22
KR100493836B1 (ko) 2005-06-08
HK1050839A1 (en) 2003-07-11
CA2388609A1 (en) 2001-05-10
MXPA02004389A (es) 2002-09-02
ATE401892T1 (de) 2008-08-15
PL200273B1 (pl) 2008-12-31
CZ20021529A3 (cs) 2002-08-14
BR0015188A (pt) 2002-11-05
NO20022058L (no) 2002-06-27
US20090252793A1 (en) 2009-10-08
AU1997801A (en) 2001-05-14
KR20020049004A (ko) 2002-06-24
US20060079502A1 (en) 2006-04-13
HU227685B1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
CA2388609C (en) Oxcarbazepine formulations for administration with or without food
EP0966287B1 (en) Oxacarbazepine film-coated tablets
US20020022056A1 (en) Oxacarbazepine film-coated tablets
RU2742745C1 (ru) Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом
US20220241207A1 (en) Extended-release solid oral dosage form comprising vitamin b12 and a vitamin b12 depleting drug
HK1024423B (en) Oxacarbazepine film-coated tablets